Leaderboard

En | De
Sie sind hier: Onkologie » Urologische Tumoren 12. März 2026
Suchen
medline.ch
Urologische Tumoren
Erweiterte Suche
Dermatologie
Endokrinologie
Ernährung
Gastroenterologie
Gynäkologie
Hämatologie
Infektiologie
Kardiovaskuläre Erkrankungen
Muskuloskelettale Erkrankungen
Neurologie
Onkologie
Bewegungsapparat
Blut
Endokrine Organe
Gynäkologische Tumoren
Haut
Magen-Darm
ORL
Respirationstrakt
Urologische Tumoren
ZNS
Ophthalmologie
ORL
Pädiatrie
Psychiatrie
Respirationstrakt
Sportmedizin
Urologie-Nephrologie
Schrift: Schrift grösser Schrift kleiner

Rect Top
   Seite 1 von 8836  vorhergehende Seite nächste Seite
   
   Artikel 1 - 20 / 176705  
   
Targeted and Perilesional or Systematic Biopsies in Prostate Cancer: The TARGET Clinical Trial Protocol.
Eur Urol Oncol
Baboudjian M, Sordelli F, Patard JJ, Moussi B, Graffeille V, Basset V, Legraverend D, Bastide C, Daniel L, Beauval JB, Rouprêt M, Robert G, Ploussard G.
PMID: 41813528 [PubMed - as supplied by publisher]


From bench to bedside: translating the histone deacetylase inhibitors into prostate cancer therapies.
Clin Chim Acta
Rocha SM, Brás MB, Pereira BJ, Maia CJ.
PMID: 41812786 [PubMed - as supplied by publisher]


Reirradiation Options for Previously Irradiated Prostate Cancer: Is It Feasible to Randomise Between Treatment With Stereotactic Body Radiotherapy (SBRT) Versus High-Dose-Rate Brachytherapy?
Clin Oncol (R Coll Radiol)
Zhong J, Slevin F, Brown S, Serra M, Bownes P, Thompson C, Reed R, Reeves K, Dubec M, Eccles C, Chuter R, Tsang YM, Taylor NJ, West CML, Buckley D, Alonzi R, Scarsbrook A, Choudhury A, Hoskin P, Henry AM.
PMID: 41812301 [PubMed - as supplied by publisher]


European Study of Prostate Cancer Screening - 23-Year Follow-up.
N Engl J Med

PMID: 41812212 [PubMed - in process]


Bridging the Gap: The Role of Shared Decision-Making in Addressing Racial and Ethnic Disparities in Prostate-Specific Antigen Screening.
Oncol Nurs Forum

PMID: 41812019 [PubMed - indexed for MEDLINE]


Multi-omics study on tumor-associated macrophages remodeling the tumor microenvironment via the CXCL5-CXCR2 axis to drive immune escape in bladder cancer.
Cancer Immunol Immunother
Jiang Y, Li J, Yang Z, Ma M, Wang L, Zhang L, Jing M, Zhang Y, Pu Y, Chen Y, He J, Liu H, Qu X, Zhang M, Fan J.
PMID: 41811476 [PubMed - indexed for MEDLINE]


Incorporating the Patient Voice into Attribute and Level Selection for a Preference Study: A Qualitative Study in Non-Muscle Invasive Bladder Cancer.
Patient
Mason B, Eccleston A, Ayala-Nunes L, Hauber B, Gater A, Coulter J, Hallworth P, Thompson A, Bell B, Chang J, Brinkmann J, Cappelleri JC, Chisolm S, Satkunasivam R.
PMID: 41811417 [PubMed - as supplied by publisher]


Targeted microwave ablation of localised prostate cancer (VIOLETTE trial): a prospective multicentre study.
BJU Int
Delongchamps NB, Peltier A, Potiron E, Bladou F, Diamand R, Messas A, Roche JB, Robert G, Hoepffner JL, Piechaud T, Anract J, Velthoven RV.
PMID: 41810596 [PubMed - as supplied by publisher]


Convolutional neural networks for prostate cancer detection, classification, and segmentation: A systematic review and bibliometric analysis.
Eur J Radiol Open
Gülmez B.
PMID: 41810091 [PubMed]


Combined assessment of ERO1A expression and CD163(+) tumor-associated macrophage infiltration is superior to traditional assessment methods in predicting clear cell renal cell carcinoma prognosis.
Front Oncol
Hong T, Ren C, Xiang H, Wu H, Yu Y, Abudurexiti M, Wang Z, Wang C.
PMID: 41809819 [PubMed]


Identification of prognostic factors for postoperative recurrence-free survival in T2-stage renal cell carcinoma: a retrospective cohort study.
Transl Androl Urol
Wang Z, Qu R, Chen Y, An W, Li Y, He S, Wang W.
PMID: 41809813 [PubMed]


Development and validation of a biochemical recurrence risk assessment model for prostate cancer based on TCGA database.
Transl Androl Urol
Li M, Kang Y, Li J, Qi Q, Li M, Zhang A.
PMID: 41809812 [PubMed]


Derivation and validation of the SLNA score: a tumor size-location-number-apperance model to predict transurethral resection of bladder tumor (TURBT) complexity.
Transl Androl Urol
Zhang H, Zhang C, Xu J, Wang M, Sheng C, Xu Y, Zhu J, Zeng S, Xu C, Zhang Z.
PMID: 41809805 [PubMed]


Irreversible electroporation in prostate cancer: efficacy, tumor immune microenvironment remodeling, and combination immunotherapy-a narrative review.
Transl Androl Urol
Xiao J, Lv Z, Zhang Z, Wei H, Jiang X, Tian J.
PMID: 41809804 [PubMed]


The predictive value of multiparametric magnetic resonance imaging in enhancing prostate-specific antigen assessment for prostate cancer: a cross-sectional study.
Transl Androl Urol
Yu H, Wu J, Yang S.
PMID: 41809802 [PubMed]


Cathepsins in prostate cancer: multifunctional regulators in tumor progression and therapeutic prospects-a narrative review.
Transl Androl Urol
Zhu G, Yi X, Zhu B, Zou J, Zou X, Zhang G.
PMID: 41809789 [PubMed]


Diagnostic performance of transrectal ultrasound elastography integrated with clinical indicators in prostate cancer evaluation.
Transl Androl Urol
Dong XY, Zhou H, Sun JW, Yuan Y, Zhou XL.
PMID: 41809779 [PubMed]


Combined effect of diabetes and obesity on cancer risk in chronic kidney disease: a nationwide population-based study.
Front Endocrinol (Lausanne)
Kim CS, Suh SH, Choi HS, Bae EH, Ma SK, Jung JH, Kim B, Han KD, Kim SW.
PMID: 41809530 [PubMed - indexed for MEDLINE]


Ferroptosis: A Double-Edged Sword in Cisplatin-Based Cancer Therapy and Acute Kidney Injury.
Cancer Manag Res
Zhou S, Xiao Y, Fang L.
PMID: 41809394 [PubMed]


Impact of Surgical Wait Time on Survival After Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study.
Cancer Manag Res
Wang Q, Pei CS, Cao JY, Peng H, Niu W, Chang PA, Yao W, Zhang GH, Zhou J, Li SS, Wu JC, Wang H, Ju WB, Wang QC.
PMID: 41809390 [PubMed]


   
   Artikel 1 - 20 / 176705    Seite 1 von 8836  vorhergehende Seite nächste Seite

 
Rect Bottom
Adserver Footer
 

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

 

Übersetzungsproblem?

mehr >>

  Zeitfenster  
   

Sky right 1